Jan C Brase

Summary

Affiliation: German Cancer Research Center
Country: Germany

Publications

  1. ncbi Circulating miRNAs are correlated with tumor progression in prostate cancer
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Int J Cancer 128:608-16. 2011
  2. ncbi ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Clin Cancer Res 16:2391-401. 2010
  3. ncbi Antibody-mediated signal amplification for reverse phase protein array-based protein quantification
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center DKFZ, Heidelberg, Germany
    Methods Mol Biol 785:55-64. 2011
  4. ncbi Serum microRNAs as non-invasive biomarkers for cancer
    Jan C Brase
    Working Group Cancer Genome Research, German Cancer Research Center, Heidelberg, Germany
    Mol Cancer 9:306. 2010
  5. ncbi Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer
    Stephan Gade
    German Cancer Research Center, Cancer Genome Research, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany
    BMC Bioinformatics 12:488. 2011
  6. ncbi Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Proteome Sci 8:36. 2010
  7. ncbi Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients
    Sajo Kaduthanam
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany Translational Research Unit, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
    Lung Cancer 80:223-7. 2013
  8. ncbi ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer
    Lukasz A Kacprzyk
    Unit Cancer Genome Research, Division of Molecular Genetics, National Center for Tumor Diseases NCT and German Cancer Research Center DKFZ, Heidelberg, Germany
    PLoS ONE 8:e59976. 2013
  9. ncbi microRNA biomarkers in body fluids of prostate cancer patients
    Ruprecht Kuner
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center of Tumor Diseases, Heidelberg, Germany Electronic address
    Methods 59:132-7. 2013
  10. ncbi The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer
    Ruprecht Kuner
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center of Tumor Diseases, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
    J Mol Med (Berl) 91:237-48. 2013

Collaborators

Detail Information

Publications11

  1. ncbi Circulating miRNAs are correlated with tumor progression in prostate cancer
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Int J Cancer 128:608-16. 2011
    ..Overall, our observations suggest that miRNA-375 and miRNA-141 expression is enhanced in prostate cancer specimens and their release into the blood is further associated with advanced cancer disease...
  2. ncbi ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Clin Cancer Res 16:2391-401. 2010
    ..However, the correlation of DNA amplification, RNA levels, and protein expression and their prognostic role and association with anthracycline responses in node-negative breast cancer have not yet been evaluated...
  3. ncbi Antibody-mediated signal amplification for reverse phase protein array-based protein quantification
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center DKFZ, Heidelberg, Germany
    Methods Mol Biol 785:55-64. 2011
    ..In this chapter, we present the amplification protocol and application examples for the time-resolved analysis of signaling pathways as well as protein profiling of clinical samples...
  4. ncbi Serum microRNAs as non-invasive biomarkers for cancer
    Jan C Brase
    Working Group Cancer Genome Research, German Cancer Research Center, Heidelberg, Germany
    Mol Cancer 9:306. 2010
    ..Although several challenges remain to be addressed, circulating microRNAs have the potential to be useful for the diagnosis and prognosis of cancer diseases...
  5. ncbi Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer
    Stephan Gade
    German Cancer Research Center, Cancer Genome Research, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany
    BMC Bioinformatics 12:488. 2011
    ....
  6. ncbi Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Proteome Sci 8:36. 2010
    ..Increasing the sensitivity of RPPA approaches is important since many signaling proteins or posttranslational modifications are present at a low level...
  7. ncbi Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients
    Sajo Kaduthanam
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany Translational Research Unit, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
    Lung Cancer 80:223-7. 2013
    ..007; AUC=0.78). In conclusion, circulating miR-142-3p was found to be associated with a high risk of recurrence in early-stage lung adenocarcinoma patients, and a putative serum marker for risk assessment...
  8. ncbi ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer
    Lukasz A Kacprzyk
    Unit Cancer Genome Research, Division of Molecular Genetics, National Center for Tumor Diseases NCT and German Cancer Research Center DKFZ, Heidelberg, Germany
    PLoS ONE 8:e59976. 2013
    ..Given the prevalence of ERG fusions, TDRD1 overexpression is a common alteration in human prostate cancer which may be exploited for diagnostic or therapeutic procedures...
  9. ncbi microRNA biomarkers in body fluids of prostate cancer patients
    Ruprecht Kuner
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center of Tumor Diseases, Heidelberg, Germany Electronic address
    Methods 59:132-7. 2013
    ..We reflect the critical steps to translate miRNA biomarker into clinical routine diagnostics and present future aspects for the fast, robust and standardized quantification of miRNAs in body fluids...
  10. ncbi The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer
    Ruprecht Kuner
    Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center and National Center of Tumor Diseases, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
    J Mol Med (Berl) 91:237-48. 2013
    ....
  11. ncbi Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage
    Anne Kathleen Rupp
    Tumor Immunology Programme, D015, German Cancer Research Center, D 69120 Heidelberg, Germany
    Gynecol Oncol 122:437-46. 2011
    ..However, marker proteins that allow enrichment of tumor-derived exosomes over normal exosomes are less well defined...